Pharming Group

Pharming Group:
Building a sustainable rare disease business, preparing for approval/launch of leniolisib for APDS. Revenues >$200M (TTM) from Ruconest (marketed) for the treatment of acute hereditary angioedema (HAE) attacks including breakthrough attacks. Leniolisib, a targeted PI3Kδ inhibitor initially being developed for PI3K delta syndrome (APDS), is on track to be the first approved disease-modifying treatment for APDS, a rare genetic immunodeficiency. Regulatory approvals expected from the US FDA in Q1 2023 and EU EMA in H1 2023 under priority review/ accelerated assessment, with commercial launch expected in the US H1 and EU H2 2023. Ruconest cash flow funds leniolisib and broader pipeline development. Dual listed on Nasdaq.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Marketed, Registration Stage
Disease Space
Anti-inflammatory, Complement Mediated, Rare Disease
Finance
Profitable, Revenues
Industry
Biotechnology
Listing
Public, USA
Market Cap
500MM - 1B
Therapeutic Modalities
pi3k, Recombinant DNA, Small Molecule, Targeted Therapy
Website:
Profiles:
Address:
Vondellaan 47
Leiden, Zuid-Holland 2332AA
Netherlands
Leiden, Zuid-Holland 2332AA
Netherlands
Presentation:
More info:
My account:
Company Participants at Solebury 1x1 Management Access Event 2023
- Anurag Relan, Chief Medical Officer
- Jeroen Wakkerman, CFO
- Sijmen de Vries, CEO
Top 10 Holders of Pharming Group NV
Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
---|---|---|---|---|---|
Acadian Asset Management LLC | 3.07 | 19,982,959 | 0.00 | Stakes | 9/1/22 |
Victory Capital Management, Inc. (Investment Management) | 0.01 | 47,698 | 0.00 | Funds | 10/31/22 |
KLP Kapitalforvaltning AS | 0.02 | 117,591 | 0.00 | Funds | 11/30/22 |
Zürcher Kantonalbank (Investment Management) | 0.02 | 112,073 | 0.00 | Funds | 11/30/22 |
Link Fund Solutions (Luxembourg) SA | 0.02 | 100,000 | 0.00 | Funds | 2/28/22 |
Castlebay Investment Partners LLP | 0.02 | 100,000 | 0.00 | Funds | 11/30/22 |
BlackRock Investment Management (UK) Ltd. | 0.01 | 81,094 | 0.00 | Funds | 6/30/22 |
BlackRock Advisors (UK) Ltd. | 0.01 | 65,201 | 0.00 | Funds | 7/31/22 |
Lingohr & Partner Asset Management GmbH | 0.01 | 56,165 | 0.00 | Funds | 1/31/22 |
GAM Investment Management (Switzerland) AG | 0.01 | 55,132 | 0.00 | Funds | 11/30/22 |
Top 10 Holders of Pharming Group NV ADR RegS
Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
---|---|---|---|---|---|
Cowen Prime Advisors LLC | 0.03 | 16,700 | 0.24 | 13F | 9/30/22 |
Morgan Stanley Smith Barney LLC | 0.01 | 6,750 | 0.10 | 13F | 9/30/22 |
Geode Capital Management LLC | 0.00 | 2,093 | 0.03 | Funds | 11/30/22 |
UBS Securities LLC | 0.00 | 1,534 | 0.02 | 13F | 9/30/22 |
Wells Fargo Clearing Services LLC | 0.00 | 0 | 0.00 | 13F | 9/30/22 |
Ownership data is sourced through FactSet.
Stock Market Data
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2023 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by
QuoteMedia.
Terms of Use.